• Je něco špatně v tomto záznamu ?

Kava (Piper methysticum) Extract for the Treatment of Nervous Anxiety, Tension and Restlessness

K. Kuchta, M. Hladikova, M. Thomsen, A. Nahrstedt, M. Schmidt

. 2021 ; 71 (2) : 83-93. [pub] 20201118

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004642

AIM: Prior to the kava ban of 2002, the indication for kava (Piper methysticum) extracts defined by the German Commission E was "nervous anxiety, tension and restlessness". In 2000, an observational trial was started in Germany with the aim of defining symptoms of these indications best treated with kava extract. The trial was interrupted and archived "unevaluated" in 2001 due to the upcoming safety debate on kava. The data from this study has now been analyzed in order to identify symptoms best treated with kava. METHODS: Documentation was available from 156 patients. Twelve typical symptoms of nervous anxiety, tension and restlessness were assessed on a five-item rating scale, together with the therapeutic context, the perceived time of onset of effects and the safety of application. RESULTS: The median duration of treatment was 28 days. All individual symptoms showed significant and clinically relevant improvements. The most effective results were seen for nervous tension and restlessness, with better effects in patients with acute versus chronic complaints. The safety of the treatment was found to be excellent, which included the assessment of laboratory data. CONCLUSIONS: Overall, the study confirms the effective and safe short-term use of kava in the Commission E-defined indication of "nervous anxiety, tension and restlessness", especially in other than chronic cases. The clinical use of kava might be translated into context-related phobias according to ICD-10 F40, or to nervous tension (ICD10 R45.0) or restlessness and excitation (ICD-10 R45.1).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004642
003      
CZ-PrNML
005      
20220127145108.0
007      
ta
008      
220113s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/a-1268-7135 $2 doi
035    __
$a (PubMed)33207379
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kuchta, Kenny $u Forschungsstelle für fernöstliche Medizin, Department of Vegetation Analysis and Phytodiversity, Albrecht von Haller Institute of Plant Sciences, Georg August University, Göttingen, Germany
245    10
$a Kava (Piper methysticum) Extract for the Treatment of Nervous Anxiety, Tension and Restlessness / $c K. Kuchta, M. Hladikova, M. Thomsen, A. Nahrstedt, M. Schmidt
520    9_
$a AIM: Prior to the kava ban of 2002, the indication for kava (Piper methysticum) extracts defined by the German Commission E was "nervous anxiety, tension and restlessness". In 2000, an observational trial was started in Germany with the aim of defining symptoms of these indications best treated with kava extract. The trial was interrupted and archived "unevaluated" in 2001 due to the upcoming safety debate on kava. The data from this study has now been analyzed in order to identify symptoms best treated with kava. METHODS: Documentation was available from 156 patients. Twelve typical symptoms of nervous anxiety, tension and restlessness were assessed on a five-item rating scale, together with the therapeutic context, the perceived time of onset of effects and the safety of application. RESULTS: The median duration of treatment was 28 days. All individual symptoms showed significant and clinically relevant improvements. The most effective results were seen for nervous tension and restlessness, with better effects in patients with acute versus chronic complaints. The safety of the treatment was found to be excellent, which included the assessment of laboratory data. CONCLUSIONS: Overall, the study confirms the effective and safe short-term use of kava in the Commission E-defined indication of "nervous anxiety, tension and restlessness", especially in other than chronic cases. The clinical use of kava might be translated into context-related phobias according to ICD-10 F40, or to nervous tension (ICD10 R45.0) or restlessness and excitation (ICD-10 R45.1).
650    _2
$a anxiolytika $x farmakologie $7 D014151
650    _2
$a úzkost $x farmakoterapie $7 D001007
650    _2
$a úzkostné poruchy $x farmakoterapie $7 D001008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kava $x chemie $7 D020901
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fytoterapie $x metody $7 D008517
650    _2
$a rostlinné extrakty $x farmakologie $7 D010936
650    _2
$a prospektivní studie $7 D011446
651    _2
$a Německo $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Hladikova, Marie $u Department of Medical Informatics, 2nd Faculty of Medicine. Charles University, Prague, Czech Republic
700    1_
$a Thomsen, Michael $u Discipline of Pharmacology, The University of Sydney Medical School, Sydney, New South Wales, Australia
700    1_
$a Nahrstedt, Adolf $u Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Münster, Germany
700    1_
$a Schmidt, Mathias $u Herbresearch Germany, Tussenhausen, Germany
773    0_
$w MED00208713 $t Drug research $x 2194-9387 $g Roč. 71, č. 2 (2021), s. 83-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33207379 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145105 $b ABA008
999    __
$a ok $b bmc $g 1751950 $s 1155791
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 71 $c 2 $d 83-93 $e 20201118 $i 2194-9387 $m Drug research $n Drug Res (Stuttg) $x MED00208713
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace